isolation of NK cells from additional unstimulated leukapheresis products. In contrast, the aim of our approach was not to obtain a pure population of NK cells but to combine the donation of both stem cells and stimulated effector cells. As bone marrow insufficiency occurred in all patients after induction chemotherapy, the stem cell component of our IL-15-stimulated grafts was of great clinical importance: a fast hematopoietic recovery (including T cells) could be observed and enabled further maintenance therapy. Thus, with our approach no additional leukapheresis was necessary and depletion of unwanted cells was done in one step. IL-15 was more potent in short-time stimulation compared with IL-2, and administration of those cell products was well tolerated without any acute and late side effects, especially without induction of GvHD.
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome Leukemia (2012) 26, 2439-2441; doi:10.1038/leu.2012.162
Identification of the karyotypically occult fusion oncogene FIP1L1-PDGFRA by Cools et al. 1 in 2003 provided the molecular basis for the dramatic response to imatinib therapy in a subset of patients with eosinophilia. [2] [3] [4] As per the World Health Organization (WHO), patients harboring this molecular abnormality are classified as 'Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1'. Ever since the original report was published, several studies have described the clinico-pathological features of this disease entity and confirmed the achievement of rapid and complete clinical and hematological responses with imatinib at doses ranging from 100 to 400 mg/day. [5] [6] [7] [8] [9] [10] [11] The majority of patients also achieve molecular remission with imatinib therapy, with clinical responses being durably maintained on imatinib doses as low as 50-200 mg/week. 9, 12 Discontinuation of imatinib therapy is associated with molecular relapse within weeks to months, which may be reversible on treatment resumption; 8, 10, 11, 13 secondary resistance to imatinib is relatively rare and occurs in the context of accelerated or blast phase disease and acquisition of PDGFRA T674I and/or D842V mutations. 14 The objective of the current paper is to describe the long-term natural history of eosinophilia patients with the FIP1L1-PDGFRA mutation seen at our institution.
The current study was approved by the Mayo Clinic institutional review board. Consecutive patients with mutated FIP1L1-PDGFRA seen at our institution were identified by querying the institutional cytogenetics database. A review of clinical, laboratory and histological material confirmed the diagnosis of 'Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1'. Clinical and laboratory parameters were obtained at the time of first referral. FIP1L1-PDGFRA was identified by fluorescence in situ hybridization (FISH). One of two FISH strategies were used depending upon the time frame during which the patient was seen: either the earlygeneration consecutive 1-and 2-color, 7 or the more recent 3-color FISH assay(s) were employed. 15 Patients' information was updated in March 2012 through a review of patient histories and correspondence, social security death index or a telephone call to the patient or their local physician. The primary analysis was to examine the overall survival (OS); patients were stratified on the basis of imatinib use. OS curves were prepared by the Kaplan-Meier method and compared by using the log-rank test. P-values o0.05 were considered significant. The Statview (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.
Clinical data have been previously reported for 11 of the current 22 patients. 5, 7, 12 Imatinib response criteria have been previously published. 7 A total of 22 patients with mutated FIP1L1-PDGFRA were studied; their relevant clinical and laboratory characteristics are presented in Table 1 . In all, 19 patients either presented with or were seen in follow-up for a primary eosinophilic disorder at our institution after the discovery of FIP1L1-PDGFRA (circa 2002); of these, 18 patients were treated with imatinib. Three other patients were retrospectively identified as harboring FIP1L1-PDGFRA upon analysis of archived samples (collected from 1994 to 1997), as part of the development/validation process for internal FISH assays; none of these patients received imatinib treatment.
Not surprisingly, all patients were male and had eosinophilia at presentation; the median absolute eosinophil count (AEC) was 5.3 Â 10 9 /l (range 1-110). A significant proportion presented with fatigue, bone pain and/or other constitutional symptoms. The proportion of patients with involvement of skin, lungs, heart, gut and nervous system was roughly similar. There was a wide variation in the percentage of bone marrow nuclei harboring FIP1L1-PDGFRA by FISH (8.5-95.5%); however, the confounding effect of recent or concurrent corticosteroid treatment cannot be discounted. Median follow-up for the imatinib-treated patients (n ¼ 18) was 72.9 months (range 4.9-205.4); one patient started imatinib treatment prior to the discovery of FIP1L1-PDGFRA.
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All three patients who were retrospectively identified had cardiac involvement; in addition, one patient had hepatic infiltration with eosinophils/abnormal mast cells. Two of the three patients have died; the cause of death is known for one case, namely, leukemic transformation 24 months following diagnosis.
One patient remains alive 213 months after diagnosis. He was treated with high-dose corticosteroids and underwent emergent cardiac surgery (biventricular thrombectomy/endocardial resection with tricuspid valve replacement). Subsequent steroid-sparing treatment strategies included interferon-a (IFN-a) and/or hydroxyurea (HU); to our knowledge, this patient has not received imatinib treatment. The other two patients were treated with corticosteroids/ IFN-a and corticosteroids/IFN-a/HU/cyclosporine-A/2-chlorodeoxyadenosine, respectively.
Of the 19 contemporaneous patients, 18 were treated with imatinib; the starting dose was 100 mg/day in 14 patients, and 400 mg/day, 200 mg/day, 100 mg thrice weekly and 100 mg twice weekly for one patient each. All imatinib-treated patients, except one, achieved complete hematological remission (CHR). The sole patient without CHR was intolerant to imatinib, leading to treatment discontinuation; currently he is asymptomatic and remains off treatment with an AEC of 1-1.5 Â 10 9 /l. Another patient discontinued imatinib after 1 year of his own volition; by report, he has not had recurrent eosinophilia after 5 years of follow-up, although confirmation is lacking as he has not returned to our institution. One patient was lost to follow-up. All 10 patients who were studied post imatinib treatment achieved complete molecular remission (CMR) by FISH. The most recent recorded imatinib maintenance dose in the remaining patients is 100 mg/ day (n ¼ 4), 100 mg/week (n ¼ 3), 100 mg thrice weekly (n ¼ 3), 100 mg twice weekly (n ¼ 1), 100 mg every other day (n ¼ 1) and 50 mg every other day (n ¼ 1). Two deaths have occurred to date. The imatinib-naive patient was treated with corticosteroids; he died of complications related to pancreatitis before imatinib treatment could be initiated. The other death was due to transformation to acute myeloid leukemia (AML); in this patient, the baseline bone marrow (8 months prior) showed many clusters of very immature eosinophil precursors that were CD34 þ by immunohistochemistry, thereby suggesting accelerated disease at presentation. PDGFRA T674I or D842V mutation status was not available for this patient either at presentation or at relapse. Letters to the Editor Survival of imatinib-treated patients (n ¼ 18; median survival not reached) is illustrated in Figure 1 . The four patients who received non-imatinib therapy had a median survival of 10.3 months.
Notable aspects of the current study are the long-term followup after diagnosis and description of clinical outcome in a subset of FIP1L1-PDGFRA-mutated patients who were imatinib-naive. Given the retrospective nature of the study, the imatinib-treated and -untreated groups cannot be directly compared. Regardless, the analysis confirms the excellent survival outcome of FIP1L1-PDGFRA-mutated patients who receive imatinib therapy. The risk of leukemic transformation in the current study was not trivial (9%), although a more definitive estimate in this regard will require study of more patients; the sole imatinib-treated patient who developed AML in the current cohort likely had evolving leukemia at presentation. Overall, imatinib treatment results in excellent disease control, with remissions being maintained at very low doses, confirming the significantly increased sensitivity of FIP1L1-PDGFRA to inhibition by imatinib, as compared with BCR-ABL. These data also confirm the low likelihood of developing secondary resistance to imatinib in this setting, as compared with chronic myeloid leukemia. For these reasons, it is unlikely to be clinically useful to monitor the depth of molecular response with imatinib therapy in FIP1L1-PDGFRAmutated patients, with rare exception. A significant proportion of patients in this cohort had cardiac involvement that resulted in significant morbidity and mortality in the imatinib-naive patients. Finally, no conclusion is possible regarding the lack of overt disease relapse in the single patient who discontinued imatinib therapy after achieving CMR. Our current view is that FIP1L1-PDGFRA-mutated patients should continue imatinib therapy indefinitely to maintain response. 
